Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06900920 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Study sites: 54 to 53 · Start date changed from estimate of May 2025 to Apr 30, 2025v3 Show 2 more changesShow less
    • Study sites: 54 to 53
    • Start date changed from estimate of May 2025 to Apr 30, 2025
  2. Study sites: 1 to 54v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized, double-blind, placebo-controlled Phase III clinical study designed to demonstrate that TQB3473 tablets significantly improve the sustained response rate compared to placebo in adult patients with chronic ITP who have previously received standard corticosteroid therapy and have failed or relapsed after at least one standard ITP treatment. The study consists of a treatment period and a safety follow-up period.
Trial Details
NCT Number NCT06900920
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Primary Immune Thrombocytopenia
Enrollment 199 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov